Have your say on the new BP vector copy number quantification guidance

Our consultation on best practice guidance on the application of vector copy number quantification for the cell and gene therapy community. Part I: Adeno-associated virus and Part II: Lentivirus and Retrovirus is open until 27^th September 2021.

We would like to hear your views about the value and content of this guideline, as well as any feedback you have about similar work that would further support the quality and development of cell and gene therapies.  

To find out more and contribute, read about the consultation